Nifty
Sensex
:
:
10607.35
36012.93
55.65 (0.53%)
169.23 (0.47%)

Pharmaceuticals & Drugs - API

Rating :
73/99  (View)

BSE: 532482 | NSE: GRANULES

209.00
1.20 (0.58%)
03-Jul-2020 | 3:59PM
  • Day's Open
  • Day's High
  • Day's Low
  • Previous Close
  •  209.30
  •  214.00
  •  207.50
  •  207.80
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  2434422
  •  5087.94
  •  224.45
  •  84.00

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 5,281.99
  • 15.75
  • 1
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 6,184.13
  • 0.48%
  • 2.86

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 42.86%
  • 5.49%
  • 24.25%
  • FII
  • DII
  • Others
  • 21.7%
  • 0.01%
  • 5.69%

Chart

Price | P:E | P:BV | EV:EBITDA

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 17.33
  • 12.01
  • 17.34

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 20.11
  • 12.98
  • 5.14

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 19.98
  • 15.60
  • 10.32

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 15.99
  • 17.77
  • 14.87

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 2.72
  • 3.07
  • 2.10

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 9.18
  • 10.57
  • 9.97

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 20
Mar 19
Var%
Dec 19
Dec 18
Var%
Sep 19
Sep 18
Var%
Jun 19
Jun 18
Var%
Net Sales
600
613
-2%
704
632
11%
700
581
20%
595
453
31%
Expenses
500
516
-3%
541
518
4%
556
480
16%
477
381
25%
EBITDA
100
98
2%
163
113
44%
144
101
43%
119
73
63%
EBIDTM
17%
16%
23%
18%
21%
17%
20%
16%
Other Income
23
2
1098%
4
6
-40%
9
4
107%
2
15
-87%
Interest
7
7
-4%
7
7
-10%
7
8
-10%
7
7
5%
Depreciation
39
27
42%
39
27
44%
30
27
14%
29
25
17%
PBT
137
65
110%
89
85
5%
115
71
63%
85
56
51%
Tax
44
20
120%
25
26
-6%
19
23
-17%
27
19
42%
PAT
92
45
105%
64
58
10%
96
47
103%
58
37
55%
PATM
15%
7%
9%
9%
14%
8%
10%
8%
EPS
3.63
1.77
105%
2.52
2.29
10%
3.77
1.86
103%
2.27
1.46
55%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Net Sales
2,599
2,279
1,685
1,411
1,357
1,293
1,096
764
654
475
461
Net Sales Growth
14%
35%
19%
4%
5%
18%
43%
17%
38%
3%
 
Cost Of Goods Sold
1,281
1,256
896
680
725
747
645
467
414
296
275
Gross Profit
1,318
1,024
788
731
632
546
451
297
240
180
186
GP Margin
51%
45%
47%
52%
47%
42%
41%
39%
37%
38%
40%
Total Expenditure
2,073
1,895
1,406
1,112
1,081
1,084
938
679
575
419
400
Power & Fuel Cost
-
58
48
39
35
46
37
38
26
23
19
% Of Sales
-
3%
3%
3%
3%
4%
3%
5%
4%
5%
4%
Employee Cost
-
210
165
140
118
107
86
60
45
33
28
% Of Sales
-
9%
10%
10%
9%
8%
8%
8%
7%
7%
6%
Manufacturing Exp.
-
158
121
89
67
51
39
24
19
15
31
% Of Sales
-
7%
7%
6%
5%
4%
4%
3%
3%
3%
7%
General & Admin Exp.
-
100
83
68
60
60
44
27
21
17
18
% Of Sales
-
4%
5%
5%
4%
5%
4%
4%
3%
3%
4%
Selling & Distn. Exp.
-
92
83
81
68
72
85
62
48
32
28
% Of Sales
-
4%
5%
6%
5%
6%
8%
8%
7%
7%
6%
Miscellaneous Exp.
-
23
9
16
9
2
2
2
1
3
28
% Of Sales
-
1%
1%
1%
1%
0%
0%
0%
0%
1%
0%
EBITDA
525
384
278
299
276
209
158
85
79
56
61
EBITDA Margin
20%
17%
17%
21%
20%
16%
14%
11%
12%
12%
13%
Other Income
37
27
11
10
6
4
4
2
1
1
12
Interest
27
28
33
32
37
32
20
18
17
12
18
Depreciation
137
105
76
72
58
53
30
23
21
18
19
PBT
426
277
180
205
186
128
112
46
43
27
38
Tax
116
89
63
65
61
37
37
14
13
6
7
Tax Rate
27%
32%
35%
32%
33%
29%
33%
30%
30%
22%
19%
PAT
310
188
117
140
125
91
75
33
30
21
30
PAT before Minority Interest
310
188
117
140
125
91
75
33
30
21
30
Minority Interest
0
0
0
0
0
0
0
0
0
0
0
PAT Margin
12%
8%
7%
10%
9%
7%
7%
4%
5%
4%
7%
PAT Growth
65%
61%
-17%
12%
37%
21%
131%
9%
43%
-31%
 
EPS
12.19
7.38
4.59
5.50
4.91
3.58
2.96
1.28
1.18
0.82
1.19

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Shareholder's Funds
1,529
1,304
904
662
431
356
275
245
220
202
Share Capital
25
25
23
22
20
20
20
20
20
22
Total Reserves
1,493
1,273
878
611
411
335
254
225
200
181
Non-Current Liabilities
553
488
188
247
357
344
202
113
59
164
Secured Loans
479
433
124
184
303
296
175
87
37
136
Unsecured Loans
0
0
0
1
1
13
1
1
1
11
Long Term Provisions
13
8
7
6
4
4
2
2
1
0
Current Liabilities
896
878
787
655
415
293
206
214
157
49
Trade Payables
323
274
216
181
188
136
92
76
52
38
Other Current Liabilities
114
70
93
79
89
48
24
31
19
9
Short Term Borrowings
454
525
474
393
125
101
85
102
83
0
Short Term Provisions
5
9
4
2
13
8
5
5
4
3
Total Liabilities
2,979
2,670
1,879
1,563
1,203
992
683
571
436
415
Net Block
944
777
644
560
617
482
263
250
239
237
Gross Block
1,473
1,200
984
823
844
654
387
354
323
303
Accumulated Depreciation
529
423
339
263
227
171
124
104
84
66
Non Current Assets
1,696
1,484
1,051
745
700
612
389
311
257
240
Capital Work in Progress
496
515
267
77
62
125
109
29
7
2
Non Current Investment
210
157
108
70
0
0
0
0
0
0
Long Term Loans & Adv.
46
36
31
38
21
4
16
30
11
0
Other Non Current Assets
0
0
0
0
0
0
0
0
0
0
Current Assets
1,282
1,187
828
818
500
377
289
260
179
174
Current Investments
0
0
0
0
0
0
9
0
0
0
Inventories
384
280
269
254
225
174
136
110
75
69
Sundry Debtors
674
628
418
375
137
111
71
95
72
66
Cash & Bank
89
116
50
130
65
42
42
32
12
13
Other Current Assets
135
49
40
10
74
50
30
23
20
26
Short Term Loans & Adv.
98
114
52
49
2
29
17
13
12
23
Net Current Assets
386
309
41
163
85
84
83
47
22
125
Total Assets
2,979
2,670
1,879
1,563
1,203
992
683
571
436
415

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Cash From Operating Activity
262
-1
188
151
150
108
91
26
49
60
PBT
277
180
205
186
128
112
46
43
27
38
Adjustment
150
107
95
93
85
50
41
38
33
25
Changes in Working Capital
-76
-230
-52
-80
-31
-31
15
-44
-6
3
Cash after chg. in Working capital
351
57
248
199
182
132
102
37
54
66
Interest Paid
0
0
0
0
0
0
0
0
0
0
Tax Paid
-88
-58
-60
-48
-32
-24
-11
-12
-6
-6
Other Direct Exp. Paid
0
0
0
0
0
0
0
0
0
0
Extra & Other Items
0
0
0
0
0
0
0
0
0
0
Cash From Investing Activity
-270
-462
-326
-162
-146
-255
-128
-54
-25
-13
Net Fixed Assets
-176
-282
-250
-76
-232
-65
-89
-55
-23
-11
Net Investments
-431
0
14
-16
73
-95
-18
-10
0
-1
Others
338
-180
-90
-70
13
-95
-21
10
-2
-2
Cash from Financing Activity
-17
529
56
86
19
147
46
49
-25
-46
Net Cash Inflow / Outflow
-25
66
-82
75
24
0
10
20
-1
1
Opening Cash & Equivalents
108
42
124
55
42
42
32
12
13
13
Closing Cash & Equivalent
83
108
42
130
65
42
42
32
12
13

Financial Ratios

Consolidated /

Standalone
Description
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Book Value (Rs.)
60
51
39
29
21
17
13
12
11
10
ROA
7%
5%
8%
9%
8%
9%
5%
6%
5%
7%
ROE
13%
11%
18%
24%
23%
24%
13%
13%
10%
16%
ROCE
13%
11%
17%
20%
19%
20%
13%
15%
11%
16%
Fixed Asset Turnover
1.71
1.55
1.59
1.66
1.77
2.14
2.11
1.96
1.54
1.58
Receivable days
104
113
101
68
33
30
39
46
52
50
Inventory Days
53
59
66
63
55
51
57
51
54
50
Payable days
55
62
65
60
54
44
44
40
39
30
Cash Conversion Cycle
102
110
102
71
35
37
52
57
68
70
Total Debt/Equity
0.65
0.75
0.73
1.01
1.14
1.25
1.00
0.83
0.63
0.73
Interest Cover
11
6
7
6
5
6
4
4
3
3

News Update


  • Granules India’s arm issues voluntarily recall Metformin Hydrochloride Extended-Release Tablets
    3rd Jul 2020, 10:44 AM

    Granules’ test results showed NDMA levels above the FDA acceptable limit in 1 out of the 12 batches distributed to the US market

    Read More
  • Granules India’s arm gets USFDA’s nod for Vigabatrin for Oral Solution
    27th Apr 2020, 09:07 AM

    It is bioequivalent to the reference listed drug product, Sabril for Oral Solution, 500 mg, of Lundbeck Pharmaceuticals LLC

    Read More
  • Granules India’s arm gets USFDA’s nod for Trospium Chloride Extended-Release Capsules
    24th Apr 2020, 11:31 AM

    Trospium Chloride Extended-Release Capsules are a muscarinic antagonist indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency

    Read More
  • Granules India’s arm gets USFDA’s nod for Butalbital, Acetaminophen and Caffeine Capsules
    9th Apr 2020, 11:31 AM

    Butalbital, Acetaminophen and Caffeine Capsules are used for the relief of the symptom complex of tension headache

    Read More
  • Granules receives EU GMP approval for Visakhapatnam facility
    8th Apr 2020, 09:10 AM

    This approval is valid for three years

    Read More

Source: www.accordfintech.com. Price feed provided by www.nseindia.com and www.bseindia.com value addition by www.accordfintech.com. Intraday data delayed 15 minutes.

DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.